Page last updated: 2024-09-05

razaxaban and apixaban

razaxaban has been researched along with apixaban in 5 studies

Compound Research Comparison

Studies
(razaxaban)
Trials
(razaxaban)
Recent Studies (post-2010)
(razaxaban)
Studies
(apixaban)
Trials
(apixaban)
Recent Studies (post-2010) (apixaban)
20022,4052552,250

Protein Interaction Comparison

ProteinTaxonomyrazaxaban (IC50)apixaban (IC50)
Coagulation factor XHomo sapiens (human)0.22

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alexander, RS; He, K; Knabb, RM; Koch, S; Lam, PY; Luettgen, JM; Orwat, MJ; Pinto, DJ; Rendina, AR; Rossi, KA; Smallwood, A; Wexler, RR; Wong, PC; Xin, B1
He, K; King, SR; Knabb, RM; Lam, PY; Luettgen, JM; Qiao, JX; Rendina, AR; Wexler, RR; Wong, PC; Xin, B1
Alexander, RS; Amparo, E; Kish, K; Knabb, RM; Luettgen, JM; Morin, P; Pinto, DJ; Quan, ML; Rossi, KA; Sheriff, S; Smallwood, A; Wexler, RR; Woerner, FJ1
Cheney, DL; Knabb, RM; Pinto, DJ; Smallheer, JM; Wexler, RR1
Barrett, YC; Frost, C; Shenker, A; Wang, Z1

Reviews

1 review(s) available for razaxaban and apixaban

ArticleYear
Factor Xa inhibitors: next-generation antithrombotic agents.
    Journal of medicinal chemistry, 2010, Sep-09, Volume: 53, Issue:17

    Topics: Administration, Oral; Animals; Anticoagulants; Biological Availability; Clinical Trials as Topic; Drug Design; Drug Evaluation, Preclinical; Factor Xa Inhibitors; Hemostasis; Humans; Models, Molecular; Protein Conformation; Structure-Activity Relationship; Thrombosis

2010

Other Studies

4 other study(ies) available for razaxaban and apixaban

ArticleYear
Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation fa
    Journal of medicinal chemistry, 2007, Nov-01, Volume: 50, Issue:22

    Topics: Administration, Oral; Animals; Biological Availability; Blood Coagulation; Crystallography, X-Ray; Dogs; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; In Vitro Techniques; Models, Molecular; Molecular Structure; Pyrazoles; Pyridones; Rabbits; Structure-Activity Relationship

2007
Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties.
    Bioorganic & medicinal chemistry letters, 2009, Jan-15, Volume: 19, Issue:2

    Topics: Animals; Caco-2 Cells; Factor Xa Inhibitors; Humans; Pyridones; Rabbits; Serine Proteinase Inhibitors; Structure-Activity Relationship

2009
Phenyltriazolinones as potent factor Xa inhibitors.
    Bioorganic & medicinal chemistry letters, 2010, Feb-15, Volume: 20, Issue:4

    Topics: Anticoagulants; Crystallography, X-Ray; Drug Design; Factor Xa Inhibitors; Humans; Isoxazoles; Models, Molecular; Molecular Structure; Pyrazoles; Pyridones; Sulfones

2010
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
    Thrombosis and haemostasis, 2010, Volume: 104, Issue:6

    Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Monitoring; Factor Xa Inhibitors; Humans; International Normalized Ratio; Isoxazoles; Morpholines; Predictive Value of Tests; Prothrombin Time; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban; Thiophenes; Venous Thromboembolism

2010